RedHill Biopharma (RDHL) Intangibles (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Intangibles data on file, last reported at $5.3 million in Q4 2025.

• Intangibles for Q4 2025 came in at $5.3 million, down 4.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.3 million (down 4.62% YoY), and the FY2025 annual result was $5.3 million, down 4.62% from the prior year.
• Intangibles eased to $5.3 million in Q4 2025 per RDHL's latest filing, from $5.5 million in the prior quarter.
• Over five years, Intangibles peaked at $89.4 million in Q4 2021 and troughed at $5.3 million in Q4 2025.
• A 5-year average of $39.9 million and a median of $11.8 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2021 and 2022: Intangibles soared 442.88% in 2021, then slumped 93.56% in 2022.
• A 5-year view of Intangibles shows it stood at $89.4 million in 2021, then tumbled by 93.56% to $5.8 million in 2022, then jumped by 104.76% to $11.8 million in 2023, then plunged by 52.94% to $5.5 million in 2024, then decreased by 4.62% to $5.3 million in 2025.
• Business Quant data shows RDHL's Intangibles at $5.3 million in Q4 2025, $5.5 million in Q2 2025, and $5.5 million in Q4 2024.